CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

Dapagliflozin for treating chronic heart failure with reduced ejection fraction A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: rationale, design, and baseline patient characteristics. Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association Heart Failure With Improved Ejection Fraction-Is it Possible to Escape One’s Past? Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction

Original Research2020 Oct 20;33(3):108288.

JOURNAL:Cell Rep. Article Link

Prdm16 Deficiency Leads to Age-Dependent Cardiac Hypertrophy, Adverse Remodeling, Mitochondrial Dysfunction, and Heart Failure

DM Cibi, KW Bi-Lin, MK Singh et al. Keywords: EHMT1/2; Myc; Prdm16; aging; cardiac fibrosis; cardiac hypertrophy; cardiac metabolism; heart failure; mitochondrial defects

Full Text PDF